Premium
Na + /Ca 2+ Exchange as a Drug Target—Insights from Molecular Pharmacology and Genetic Engineering
Author(s) -
IWAMOTO TAKAHIRO
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1387.039
Subject(s) - chemistry , efflux , pharmacology , intracellular , transporter , gene isoform , biophysics , membrane potential , membrane transport , sodium calcium exchanger , membrane , biochemistry , gene , biology
The Na + /Ca 2+ exchanger (NCX) is an ion transporter that exchanges Na + and Ca 2+ in either Ca 2+ ‐efflux or Ca 2+ ‐influx mode, depending on membrane potential and transmembrane ion gradients. In myocytes, neurons, and renal tubular cells, NCX is thought to play an important role in the regulation of intracellular Ca 2+ concentration. So far the benzyloxyphenyl derivatives (KB‐R7943, SEA0400, SN‐6, and YM‐244769) have been developed as selective NCX inhibitors. These inhibitors possess different isoform selectivities, although they have similar properties, such as Ca 2+ ‐influx mode selectivity and I 1 inactivation‐dependence. Site‐directed mutageneses have revealed that these inhibitors possess some molecular determinants (Phe‐213, Val‐227, Tyr‐228, Gly‐833, and Asn‐839) for interaction with NCX1. These benzyloxyphenyl derivatives are expected to be useful tools to study the physiological roles of NCX. Interestingly, benzyloxyphenyl NCX inhibitors effectively prevent several ischemia–reperfusion injuries and salt‐dependent hypertension in animal models. Furthermore, several experiments with genetically engineered mice provide compelling evidence that these diseases are triggered by pathological Ca 2+ entry through NCX1. Thus, NCX inhibitors may have therapeutic potential as novel drugs for reperfusion injury and salt‐dependent hypertension.